BioLine Rx Earnings Estimates, EPS & Revenue | NASDAQ:BLRX

Comments

BioLine Rx Ltd Earnings Estimates

BLRXNASDAQ

Trade with Public

$2.65

-0.0594-2.19%

At close: Mar 20, 5:00 PM EST

$2.66

0.010.38%

After Hours: Mar 20, 7:47 PM EST

Earnings: Q4 2025 earnings tomorrow on Mon Mar 23rd before the market open

Conference Call: Conference call scheduled tomorrow at 8:30 AM

Click to view the webcast

Overview NewsEarningsOptions Analyst Ratings Short Interest Stock Report

BioLine Rx Earnings Estimates, EPS & Revenue | NASDAQ:BLRX

BioLine Rx (BLRX) is scheduled to report Q4 earnings on March 23, 2026. Analysts estimate EPS of $-0.54 and quarterly revenue of $651.60K.

In the most recent quarter (Q3), BioLine Rx reported EPS of $-0.22, beating estimates of $-0.49 by 0.55%. Revenue came in at $427.00K, missing the estimate of $606.00K by 0.30%.

Over the last 4 quarters, BioLine Rx has averaged an EPS surprise of 0.67% and a revenue surprise of 0.46%.

Earnings Date

Mar 23

EPS Estimate

$-0.540

Quarterly Revenue Estimate

$651.60K

Annual Revenue
(as of Sep 30)

$12.73M

BioLine Rx Earnings History

Analyze the earnings history of BioLine Rx using advanced sorting and filters.

Loading calendar...

BioLine Rx (BLRX) Earnings Per Share

The chart below shows BioLine Rx's reported EPS compared to analyst estimates over recent quarters.

BioLine Rx (BLRX) Revenue

The chart below shows BioLine Rx's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is BioLine Rx (NASDAQ:BLRX) reporting earnings?

BioLine Rx (BLRX) is scheduled to report earnings on March 23, 2026. The last reported earnings were for reported on November 24, 2025 for Q3.

What were the latest earnings per share (EPS) for BioLine Rx (NASDAQ:BLRX)?

The Actual EPS was $-0.22, which beat the estimate of $-0.49.

What were BioLine Rx’s (NASDAQ:BLRX) revenues?

The Actual Revenue was $427.00K, which missed the estimate of $606.00K.

People Also Watch

Bolt Biotherapeutics Inc

NASDAQ:BOLT

$4.76

AlphaTON Capital Corp

NASDAQ:ATON

$0.35

-1.98%

CollPlant Biotechnologies Ltd

NASDAQ:CLGN

$0.61

-0.02%

TransCode Therapeutics Inc

NASDAQ:RNAZ

$9.00

0.22%

Alaunos Therapeutics Inc

NASDAQ:TCRT

$3.28

1.86%

BioLine Rx Earnings Estimates, EPS & Revenue | NASDAQ:BLRX

BioLine Rx (BLRX) is scheduled to report Q4 earnings on March 23, 2026. Analysts estimate EPS of $-0.54 and quarterly revenue of $651.60K.

In the most recent quarter (Q3), BioLine Rx reported EPS of $-0.22, beating estimates of $-0.49 by 0.55%. Revenue came in at $427.00K, missing the estimate of $606.00K by 0.30%.

Over the last 4 quarters, BioLine Rx has averaged an EPS surprise of 0.67% and a revenue surprise of 0.46%.

Earnings Date

Mar 23

EPS Estimate

$-0.540

Quarterly Revenue Estimate

$651.60K

Annual Revenue
(as of Sep 30)

$12.73M